NCT02471690View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Healthy
Interventions
DRUG

Oritavancin

IV - Single dose 1200 mg Oritavancin

DRUG

Dextrose

D5W 5% in Water

Trial Locations (1)

53095

Spaulding Clinical, West Bend

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY

NCT02471690 - Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers | Biotech Hunter | Biotech Hunter